CN104523581B - 盐酸尼卡地平氯化钠注射液及其制备方法 - Google Patents
盐酸尼卡地平氯化钠注射液及其制备方法 Download PDFInfo
- Publication number
- CN104523581B CN104523581B CN201410756079.0A CN201410756079A CN104523581B CN 104523581 B CN104523581 B CN 104523581B CN 201410756079 A CN201410756079 A CN 201410756079A CN 104523581 B CN104523581 B CN 104523581B
- Authority
- CN
- China
- Prior art keywords
- sodium chloride
- licardipine hydrochloride
- injection
- chloride injection
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008354 sodium chloride injection Substances 0.000 title claims abstract description 21
- SRWFBFUYENBCGF-UHFFFAOYSA-M sodium;chloride;hydrochloride Chemical compound [Na+].Cl.[Cl-] SRWFBFUYENBCGF-UHFFFAOYSA-M 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 20
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229960001783 nicardipine Drugs 0.000 claims abstract description 18
- 239000011780 sodium chloride Substances 0.000 claims abstract description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 20
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- 230000001954 sterilising effect Effects 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 7
- 238000001802 infusion Methods 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 7
- 230000008901 benefit Effects 0.000 claims description 5
- 229960000583 acetic acid Drugs 0.000 claims description 4
- 230000001186 cumulative effect Effects 0.000 claims description 4
- 238000005262 decarbonization Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000012362 glacial acetic acid Substances 0.000 claims description 4
- 239000011521 glass Substances 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 239000008215 water for injection Substances 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 abstract description 14
- 230000001631 hypertensive effect Effects 0.000 abstract description 7
- 206010058179 Hypertensive emergency Diseases 0.000 abstract description 5
- 201000005857 malignant hypertension Diseases 0.000 abstract description 5
- 230000002159 abnormal effect Effects 0.000 abstract description 4
- 229940126701 oral medication Drugs 0.000 abstract description 2
- 238000012154 short term therapy Methods 0.000 abstract description 2
- 230000036772 blood pressure Effects 0.000 description 15
- 230000037396 body weight Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000002464 muscle smooth vascular Anatomy 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical group CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical group [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 208000007530 Essential hypertension Diseases 0.000 description 2
- 206010020802 Hypertensive crisis Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010058558 Hypoperfusion Diseases 0.000 description 1
- 241001585714 Nola Species 0.000 description 1
- 201000004239 Secondary hypertension Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000001174 endocardium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 201000009939 hypertensive encephalopathy Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000011169 microbiological contamination Methods 0.000 description 1
- AIKVCUNQWYTVTO-UHFFFAOYSA-N nicardipine hydrochloride Chemical compound Cl.COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 AIKVCUNQWYTVTO-UHFFFAOYSA-N 0.000 description 1
- 229960002289 nicardipine hydrochloride Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
pH值 | 分解产物+有关物质(%) |
3.0 | >3.0 |
3.5 | <3.0 |
4.0 | <2.0 |
4.5 | <3.0 |
5.0 | <3.0 |
5.5 | >3.0 |
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410756079.0A CN104523581B (zh) | 2014-12-11 | 2014-12-11 | 盐酸尼卡地平氯化钠注射液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410756079.0A CN104523581B (zh) | 2014-12-11 | 2014-12-11 | 盐酸尼卡地平氯化钠注射液及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104523581A CN104523581A (zh) | 2015-04-22 |
CN104523581B true CN104523581B (zh) | 2015-11-04 |
Family
ID=52839344
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410756079.0A Active CN104523581B (zh) | 2014-12-11 | 2014-12-11 | 盐酸尼卡地平氯化钠注射液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104523581B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114831934B (zh) * | 2022-05-11 | 2023-05-26 | 回音必集团抚州制药有限公司 | 一种盐酸尼卡地平注射液的制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101484136A (zh) * | 2006-04-18 | 2009-07-15 | Ekr治疗公司 | 预混合的、立即可用的药物组合物 |
-
2014
- 2014-12-11 CN CN201410756079.0A patent/CN104523581B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101484136A (zh) * | 2006-04-18 | 2009-07-15 | Ekr治疗公司 | 预混合的、立即可用的药物组合物 |
Non-Patent Citations (1)
Title |
---|
《盐酸尼卡地平氯化钠注射液有关物质检查方法研究》;乐云峰;《药物鉴定》;20040530;第13卷(第5期);第44页 * |
Also Published As
Publication number | Publication date |
---|---|
CN104523581A (zh) | 2015-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Warren et al. | A method of obtaining renal venous blood in unanesthetized persons with observations on the extraction of oxygen and sodium para-amino hippurate | |
CN104224829A (zh) | 一种钠钾镁钙葡萄糖注射液及其制备方法 | |
JP2021151485A (ja) | 階層型適応閉ループ輸液蘇生及び心血管薬投与システム | |
CN113616629A (zh) | 马兜铃烷型倍半萜类化合物在制备预防和/或治疗心脑血管疾病药物中的用途 | |
CN104523581B (zh) | 盐酸尼卡地平氯化钠注射液及其制备方法 | |
CN105287370B (zh) | 一种肌苷及其组合物注射液的制备方法 | |
CN102068408A (zh) | 一种盐酸法舒地尔注射液及其制备方法 | |
Shin et al. | Transient cortical blindness after heart surgery in a child patient-A case report | |
Burns et al. | 146: Carboxyhemoglobin associated with hemolysis as a marker of impending oxygenator failure in VA ECMO | |
CN102784098A (zh) | 丙戊酸镁注射液及其制备工艺 | |
RU2635523C2 (ru) | Способ проведения кардиоплегии | |
CN109620821A (zh) | 双氯芬酸钠在用于舒张预收缩的气管平滑肌及治疗哮喘中的应用 | |
Fajemiroye et al. | Hypotensive and antihypertensive potential of 4-[(1-phenyl-1H-pyrazol-4-yl) methyl] 1-piperazine carboxylic acid ethyl ester: A piperazine derivative | |
CN103494837B (zh) | 一种血容量扩充药物组合物及其制备方法与应用 | |
Smith | The coronary circulation | |
Zhou et al. | A3679 Effect of empty-nest on variability of self-measured blood pressure at home in elderly hypertension patients | |
Baizhigitov et al. | Methods of modified ultrafiltration in the surgical correction of transposition of the great arteries in newborns | |
Wang et al. | A5889 Metabolic Syndrome and Lower Oxyhemoglobin Saturation in Tibet Autonomous Region, China | |
Wang et al. | A9949 Blood Pressure Components and Reduced Kidney Function in Xinjiang Population | |
CN104173343A (zh) | 一种米力农化合物及含有该化合物的药物组合物 | |
Crawford et al. | A review of extracorporeal membrane oxygenation in the UK | |
CN105622528B (zh) | 一种治疗肺动脉高压的化合物及其应用 | |
Welling et al. | Brain Death and Management of the Potential Donor | |
Runyan et al. | Left Ventricular Assist Devices vs. the Total Artificial Heart: Which Causes More Cerebrovascular Accidents? | |
CN102727511A (zh) | 一种舒张血管的中药活性成分配伍 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: 331800 No. 6, Dongshan Industrial Park, Dongxiang Economic Development Zone, Fuzhou, Jiangxi. Patentee after: HUIYINBI GROUP JIANGXI EAST ASIA PHARMACEUTICAL Co.,Ltd. Address before: 331800 Dongxiang Province Economic Development Zone, Dongshan Industrial Park, Fuzhou, Hui Road, No. 6, No. Patentee before: HUIYINBI GROUP (JIANGXI) EAST ASIA PHARMACEUTICAL CO.,LTD. |
|
CP03 | Change of name, title or address | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221221 Address after: 344000 Jiangxi province Fuzhou City Jinchao Development Zone Zhong Ling Industrial Park Patentee after: HUIYINBI GROUP FUZHOU PHARMACEUTICAL Co.,Ltd. Address before: 331800 No. 6, Dongshan Industrial Park, Dongxiang Economic Development Zone, Fuzhou, Jiangxi. Patentee before: HUIYINBI GROUP JIANGXI EAST ASIA PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231011 Address after: 331800 No. 6, Dongshan Industrial Park, Dongxiang Economic Development Zone, Fuzhou, Jiangxi. Patentee after: HUIYINBI GROUP JIANGXI EAST ASIA PHARMACEUTICAL Co.,Ltd. Address before: 344000 Jiangxi province Fuzhou City Jinchao Development Zone Zhong Ling Industrial Park Patentee before: HUIYINBI GROUP FUZHOU PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right |